- Home
- NHS vs TLSA Comparison
NHS vs TLSA Comparison
Compare NHS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- TLSA
- Stock Information
- Founded
- NHS 2003
- TLSA 2013
- Country
- NHS United States
- TLSA United Kingdom
- Employees
- NHS N/A
- TLSA N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- NHS Finance
- TLSA Health Care
- Exchange
- NHS Nasdaq
- TLSA Nasdaq
- Market Cap
- NHS 226.7M
- TLSA 240.0M
- IPO Year
- NHS N/A
- TLSA 2000
- Fundamental
- Price
- NHS $7.36
- TLSA $1.94
- Analyst Decision
- NHS
- TLSA
- Analyst Count
- NHS 0
- TLSA 0
- Target Price
- NHS N/A
- TLSA N/A
- AVG Volume (30 Days)
- NHS 111.8K
- TLSA 423.0K
- Earning Date
- NHS 01-01-0001
- TLSA 05-06-2025
- Dividend Yield
- NHS 13.44%
- TLSA N/A
- EPS Growth
- NHS N/A
- TLSA N/A
- EPS
- NHS N/A
- TLSA N/A
- Revenue
- NHS N/A
- TLSA N/A
- Revenue This Year
- NHS N/A
- TLSA N/A
- Revenue Next Year
- NHS N/A
- TLSA N/A
- P/E Ratio
- NHS N/A
- TLSA N/A
- Revenue Growth
- NHS N/A
- TLSA N/A
- 52 Week Low
- NHS $6.95
- TLSA $0.63
- 52 Week High
- NHS $9.17
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- NHS 45.10
- TLSA 48.16
- Support Level
- NHS $7.14
- TLSA $1.81
- Resistance Level
- NHS $7.36
- TLSA $2.04
- Average True Range (ATR)
- NHS 0.13
- TLSA 0.18
- MACD
- NHS -0.01
- TLSA -0.02
- Stochastic Oscillator
- NHS 40.82
- TLSA 26.92
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.